-Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced that Anne M. Fields will lead the specialty sales force that markets its asthma drug, ZYFLO(R) (zileuton tablets). Ms. Fields has served as Critical Therapeutics' Vice President of Sales since July 2005. The Company also announced that Frederick Finnegan has resigned as Senior Vice President of Sales and Marketing to pursue another opportunity.
Ms. Fields has more than 20 years of experience in successfully building, training and motivating pharmaceutical sales forces. "I am confident in Anne's ability to lead the sales force and continue to build brand awareness for ZYFLO as we prepare for the launch of the twice daily, controlled-release formulation of zileuton, pending regulatory approval," said Critical Therapeutics' Executive Chairman Bob Zeiger.
Prior to joining Critical Therapeutics, Ms. Fields was Vice President of Field Sales at MedPointe, Inc., where she successfully grew MedPointe's key in-line brands, Astelin(R), Optivar(R) and Zomig(R). Ms. Fields spent 19 years at Schering-Plough Corp. As Vice President of Sales, she led Schering-Plough's 1,500-representative primary care U.S. sales force. Her respiratory product launch experience includes Claritin(R), Clarinex(R), and Nasonex(R).
"We wish Rick well and thank him for his contributions to the Company over the past three years, including his role in the launch of our first marketed drug, ZYFLO, last fall," said Frank Thomas, Critical Therapeutics' President.
About Critical Therapeutics
Critical Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases. The Company owns worldwide rights to the asthma drug ZYFLO(R) (zileuton tablets), as well as other formulations of zileuton. ZYFLO is the only 5-lipoxygenase inhibitor approved for marketing by the U.S. Food and Drug Administration. The Company's commercialization efforts for ZYFLO are carried out by its specialty sales force. Critical Therapeutics also is developing treatments directed toward the severe inflammatory response in acute diseases and conditions that lead to admission to the emergency room or intensive care unit, and acute exacerbations of other chronic diseases that frequently lead to hospitalization.
Ms. Fields has more than 20 years of experience in successfully building, training and motivating pharmaceutical sales forces. "I am confident in Anne's ability to lead the sales force and continue to build brand awareness for ZYFLO as we prepare for the launch of the twice daily, controlled-release formulation of zileuton, pending regulatory approval," said Critical Therapeutics' Executive Chairman Bob Zeiger.
Prior to joining Critical Therapeutics, Ms. Fields was Vice President of Field Sales at MedPointe, Inc., where she successfully grew MedPointe's key in-line brands, Astelin(R), Optivar(R) and Zomig(R). Ms. Fields spent 19 years at Schering-Plough Corp. As Vice President of Sales, she led Schering-Plough's 1,500-representative primary care U.S. sales force. Her respiratory product launch experience includes Claritin(R), Clarinex(R), and Nasonex(R).
"We wish Rick well and thank him for his contributions to the Company over the past three years, including his role in the launch of our first marketed drug, ZYFLO, last fall," said Frank Thomas, Critical Therapeutics' President.
About Critical Therapeutics
Critical Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases. The Company owns worldwide rights to the asthma drug ZYFLO(R) (zileuton tablets), as well as other formulations of zileuton. ZYFLO is the only 5-lipoxygenase inhibitor approved for marketing by the U.S. Food and Drug Administration. The Company's commercialization efforts for ZYFLO are carried out by its specialty sales force. Critical Therapeutics also is developing treatments directed toward the severe inflammatory response in acute diseases and conditions that lead to admission to the emergency room or intensive care unit, and acute exacerbations of other chronic diseases that frequently lead to hospitalization.
posted by doublezero at
10:33 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home